IRIS Accounts Production v26.1.10.61 12060630 Board of Directors Board of Directors 1.4.25 31.3.26 31.3.26 30.6.26 false true false false false true false Auditors Opinion Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh120606302025-03-31120606302026-03-31120606302025-04-012026-03-31120606302024-03-31120606302024-04-012025-03-31120606302025-03-3112060630ns15:EnglandWales2025-04-012026-03-3112060630ns14:PoundSterling2025-04-012026-03-3112060630ns10:Director12025-04-012026-03-3112060630ns10:Director22025-04-012026-03-3112060630ns10:PrivateLimitedCompanyLtd2025-04-012026-03-3112060630ns10:SmallEntities2025-04-012026-03-3112060630ns10:Audited2025-04-012026-03-3112060630ns10:SmallCompaniesRegimeForDirectorsReport2025-04-012026-03-3112060630ns10:SmallCompaniesRegimeForAccounts2025-04-012026-03-3112060630ns10:FullAccounts2025-04-012026-03-311206063012025-04-012026-03-3112060630ns10:OrdinaryShareClass12025-04-012026-03-3112060630ns10:Director32025-04-012026-03-3112060630ns10:RegisteredOffice2025-04-012026-03-3112060630ns5:CurrentFinancialInstruments2026-03-3112060630ns5:CurrentFinancialInstruments2025-03-3112060630ns5:Non-currentFinancialInstruments2026-03-3112060630ns5:Non-currentFinancialInstruments2025-03-3112060630ns5:ShareCapital2026-03-3112060630ns5:ShareCapital2025-03-3112060630ns5:SharePremium2026-03-3112060630ns5:SharePremium2025-03-3112060630ns5:RetainedEarningsAccumulatedLosses2026-03-3112060630ns5:RetainedEarningsAccumulatedLosses2025-03-3112060630ns5:IntangibleAssetsOtherThanGoodwill2025-04-012026-03-3112060630ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-04-012026-03-3112060630ns5:LeaseholdImprovements2025-04-012026-03-3112060630ns5:PlantMachinery2025-04-012026-03-3112060630ns5:FurnitureFittings2025-04-012026-03-3112060630ns5:ComputerEquipment2025-04-012026-03-3112060630ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-03-3112060630ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2026-03-3112060630ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-03-3112060630ns5:LeaseholdImprovements2025-03-3112060630ns5:PlantMachinery2025-03-3112060630ns5:FurnitureFittings2025-03-3112060630ns5:ComputerEquipment2025-03-3112060630ns5:LeaseholdImprovements2026-03-3112060630ns5:PlantMachinery2026-03-3112060630ns5:FurnitureFittings2026-03-3112060630ns5:ComputerEquipment2026-03-3112060630ns5:LeaseholdImprovements2025-03-3112060630ns5:PlantMachinery2025-03-3112060630ns5:FurnitureFittings2025-03-3112060630ns5:ComputerEquipment2025-03-3112060630ns5:AdditionsToInvestments2026-03-3112060630ns5:CostValuation2026-03-3112060630ns5:WithinOneYearns5:CurrentFinancialInstruments2026-03-3112060630ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3112060630ns5:WithinOneYear2026-03-3112060630ns5:WithinOneYear2025-03-3112060630ns5:BetweenOneFiveYears2026-03-3112060630ns5:BetweenOneFiveYears2025-03-3112060630ns5:AllPeriods2026-03-3112060630ns5:AllPeriods2025-03-3112060630ns10:OrdinaryShareClass12026-03-31
REGISTERED NUMBER: 12060630 (England and Wales)














Financial Statements

for the Year Ended 31 March 2026

for

TRUPCR Europe Limited

TRUPCR Europe Limited (Registered number: 12060630)






Contents of the Financial Statements
for the Year Ended 31 March 2026




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


TRUPCR Europe Limited

Company Information
for the Year Ended 31 March 2026







DIRECTORS: H Singh
N K Dubey
D Dubey



REGISTERED OFFICE: Unit 6, Williams House
Lloyd Street North
Manchester Science Park
Manchester
M15 6SE



REGISTERED NUMBER: 12060630 (England and Wales)



SENIOR STATUTORY AUDITOR: Ian Sluckis BA FCA



AUDITORS: Freedman Frankl & Taylor
Statutory Auditors
Chartered Accountants
Reedham House
31 King Street West
Manchester
M3 2PJ

TRUPCR Europe Limited (Registered number: 12060630)

Balance Sheet
31 March 2026

2026 2025
Notes £    £   
FIXED ASSETS
Intangible assets 3 - 2,796
Tangible assets 4 68,590 73,785
Investments 5 829,500 -
898,090 76,581

CURRENT ASSETS
Stocks 6 47,039 54,473
Debtors 7 562,991 271,825
Cash at bank 393,565 559,747
1,003,595 886,045
CREDITORS
Amounts falling due within one year 8 (712,549 ) (184,234 )
NET CURRENT ASSETS 291,046 701,811
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,189,136

778,392

CREDITORS
Amounts falling due after more than one year 9 (262,500 ) (1,000 )
NET ASSETS 926,636 777,392

CAPITAL AND RESERVES
Called up share capital 11 1,000 1,000
Share premium 869,400 869,400
Retained earnings 56,236 (93,008 )
SHAREHOLDERS' FUNDS 926,636 777,392

TRUPCR Europe Limited (Registered number: 12060630)

Balance Sheet - continued
31 March 2026


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Comprehensive Income has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 30 June 2026 and were signed on its behalf by:




H Singh - Director



N K Dubey - Director


TRUPCR Europe Limited (Registered number: 12060630)

Notes to the Financial Statements
for the Year Ended 31 March 2026

1. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Significant judgements and estimates
In applying the company's accounting policies, the directors are required to make judgements, estimates and assumptions in determining the carrying amounts of assets and liabilities. The directors' judgements, estimates and assumptions are based on the best and most reliable evidence available at the time when the decisions are made, and are based on historical experience and other factors that are considered to be applicable. Due to the inherent subjectivity involved in making such judgements, estimates and assumptions, the actual results and outcomes may differ.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.

Key sources of estimation uncertainty

The key assumptions concerning the future, and other key sources of estimation uncertainty, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are disclosed below.

Assessing indicators of impairment
In assessing whether there have been any indicators of impairment assets, the directors have considered both external and internal sources of information such as market conditions and experience of recoverability. There have been no indicators of impairments identified during the current financial year.

Tangible fixed assets
Tangible fixed assets, are depreciated over their useful lives taking into account residual values, where appropriate. The actual lives of the assets and residual values are assessed annually and may vary depending on a number of factors. In re-assessing asset lives, factors such as technological innovation, product life cycles and maintenance programmes are taken into account. Residual value assessments consider issues such as future market conditions, the remaining life of the asset and projected disposal values.

Turnover
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates and value added tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Interest Income
Interest income is recognised on an accrual basis, when the entity obtains the right to receive the income.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

TRUPCR Europe Limited (Registered number: 12060630)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026

Development costs are being amortised evenly over their estimated useful life of three years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Improvements to property - The period of the lease
Plant and machinery - Straight line over 15 years
Fixtures and fittings - Straight line over 10 years
Computer equipment - Straight line over 3 years

Tangible fixed assets are recorded at cost less any tax, discounts and rebates. Subsequently they are recorded at cost less accumulated depreciation and impairment.

Government grants
Grants of a revenue nature are credited to income in the period to which they relate.

Investments in associates
Investments in associate undertakings are recognised at cost.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

TRUPCR Europe Limited (Registered number: 12060630)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026

1. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Going concern
The company's financial statements for the year ended 31 March 2026 have been prepared on a going concern basis as, after making appropriate enquiries, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future.

Contingent liabilities
Deferred consideration is recognised at the fair value of the amount expected to be paid. Where the settlement is deferred beyond normal credit terms, the liability is measured at the present value of the future payments, discounted at a market rate of interest for a similar debt instrument. The unwinding of the discount is recognised as a finance cost in the Profit and Loss account over the period of deferral.

2. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 8 (2025 - 6 ) .

3. INTANGIBLE FIXED ASSETS
Development
costs
£   
COST
At 1 April 2025
and 31 March 2026 8,389
AMORTISATION
At 1 April 2025 5,593
Amortisation for year 2,796
At 31 March 2026 8,389
NET BOOK VALUE
At 31 March 2026 -
At 31 March 2025 2,796

TRUPCR Europe Limited (Registered number: 12060630)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026

4. TANGIBLE FIXED ASSETS
Improvements Fixtures
to Plant and and Computer
property machinery fittings equipment Totals
£    £    £    £    £   
COST
At 1 April 2025 35,915 72,965 6,597 3,981 119,458
Additions 110 1,441 902 1,810 4,263
At 31 March 2026 36,025 74,406 7,499 5,791 123,721
DEPRECIATION
At 1 April 2025 28,437 12,944 1,886 2,406 45,673
Charge for year 2,530 4,897 683 1,348 9,458
At 31 March 2026 30,967 17,841 2,569 3,754 55,131
NET BOOK VALUE
At 31 March 2026 5,058 56,565 4,930 2,037 68,590
At 31 March 2025 7,478 60,021 4,711 1,575 73,785

5. FIXED ASSET INVESTMENTS
Interest
in
associate
£   
COST
Additions 829,500
At 31 March 2026 829,500
NET BOOK VALUE
At 31 March 2026 829,500

The company investments at the balance sheet date in the share capital of unlisted companies include the following:


Coris Holdings SRL
Registered office: Rue Guillaume Fouquet 11, 5032 Gembloux, Belgium
Nature of business: Activities of holding companies
%
Class of shares: holding
Ordinary shares 30.00

6. STOCKS
2026 2025
£    £   
Good for resale 47,039 54,473

TRUPCR Europe Limited (Registered number: 12060630)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Trade debtors 427,054 231,913
Other debtors 135,937 39,912
562,991 271,825

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Trade creditors 11,330 8,401
Amounts owed to group undertakings 493,233 161,904
Taxation and social security 5,022 -
Other creditors 202,964 13,929
712,549 184,234

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2026 2025
£    £   
Amounts owed to group undertakings 262,500 -
Other creditors - 1,000
262,500 1,000

10. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2026 2025
£    £   
Within one year 39,248 16,849
Between one and five years 58,872 -
98,120 16,849

11. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2026 2025
value: £    £   
1,000 Ordinary £1 1,000 1,000

TRUPCR Europe Limited (Registered number: 12060630)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026

12. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Ian Sluckis BA FCA (Senior Statutory Auditor)
for and on behalf of Freedman Frankl & Taylor

13. CONTINGENT LIABILITIES

Contingent consideration is payable in relation to the acquisition of the group undertaking. The amount recognised of £184,500 represents the directors' best estimate of the liability due under the terms of the purchase agreement, based on management’s performance expectations.

14. RELATED PARTY DISCLOSURES

During the year company was charged consultancy fees amounting to £71,950 (2025: £86,250) by a company in which a director of TRUPCR Europe Limited is also a director. At the year end, the amount owed from the company was £6,420 (2025: £6,420).

15. ULTIMATE CONTROLLING PARTY

The ultimate controlling party of TRUPCR Europe Limited is 3B BlackBio Dx Limited, which is majority shareholder incorporated and registered in India. Copies of the consolidated financial statements of 3B BlackBio Dx Ltd can be obtained from registered address 7-C, Industrial Area, Govindpura, Bhopal 462023 [M.P.], India.